Cover Image

Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients

TO THE EDITOR:Patients with hematological neoplasms, including lymphoma patients, have a high risk for severe COVID-19 diseases.1-4 COVID-19 vaccinations induce strong serologic and T-cell responses in immunocompetent humans and thereby effectively prevent severe COVID-19 disease courses.5-8 There i...

Full description

Saved in:
Bibliographic Details
Main Authors: Liebers, Nora (Author) , Speer, Claudius (Author) , Benning, Louise (Author) , Bruch, Peter-Martin (Author) , Krämer, Isabelle (Author) , Meißner, Julia (Author) , Schnitzler, Paul (Author) , Kräusslich, Hans-Georg (Author) , Dreger, Peter (Author) , Müller-Tidow, Carsten (Author) , Poschke, Isabel (Author) , Dietrich, Sascha (Author)
Format: Article (Journal) Editorial
Language:English
Published: 2022
In: Blood
Year: 2022, Volume: 139, Issue: 1, Pages: 142-147
ISSN:1528-0020
DOI:10.1182/blood.2021013445
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood.2021013445
Get full text
Author Notes:Nora Liebers, Claudius Speer, Louise Benning, Peter-Martin Bruch, Isabelle Kraemer, Julia Meissner, Paul Schnitzler, Hans-Georg Kräusslich, Peter Dreger, Carsten Mueller-Tidow, Isabel Poschke, and Sascha Dietrich
Description
Summary:TO THE EDITOR:Patients with hematological neoplasms, including lymphoma patients, have a high risk for severe COVID-19 diseases.1-4 COVID-19 vaccinations induce strong serologic and T-cell responses in immunocompetent humans and thereby effectively prevent severe COVID-19 disease courses.5-8 There is accumulating evidence that humoral immune responses after vaccination are impaired in patients with hematological malignancies, especially if they were treated with B-cell-depleting therapies such as anti-CD20 antibodies.9-11 However, there is limited information about the T-cell-mediated vaccine responses after anti-CD20 treatment. In this study, we investigated the humoral and cellular responses after COVID-19 vaccination in lymphoma patients who had received anti-CD20 treatment.
Item Description:Prepublished online on Blood first edition 20 October 2021
Gesehen am 16.09.2022
Physical Description:Online Resource
ISSN:1528-0020
DOI:10.1182/blood.2021013445

Similar Items